Clinical trials: Rivaroxaban
Neoplasm, Venous Thromboembolism
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous dalteparin in patients with cancer associated thrombosis.
- Trial name
- CASTA-DIVA (NCT02746185)
- Testing
- rivaroxaban, Low-molecular-weight heparin
- Where
- 15 sites in France
- Volunteers
- 159 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-valvular Atrial Fibrillation, Acute Coronary Syndrome
Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI
This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany.
- Conditions
- Non-valvular Atrial Fibrillation, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Antithrombotic Therapy
- Trial name
- RIVA-PCI (NCT03315650)
- Where
- 13 sites in Germany
- Volunteers
- 1,632 people
- Sponsor
- IHF GmbH - Institut für Herzinfarktforschung
Deep Vein Thrombosis
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the…
- Trial name
- NCT01516840
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Bayer
Venous Thromboembolism
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
- Trial name
- EPICT (NCT04066764)
- Testing
- Rivaroxaban, Warfarin, Nadroparin
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pulmonary Embolism, Venous Thrombosis
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery.
- Trial name
- PEPPER (NCT02810704)
- Testing
- Enteric Coated Aspirin, Warfarin, Rivaroxaban
- Where
- 32 sites in United States, Canada
- Volunteers
- 18,883 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer
Bioequivalence
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 20 mg film-coated tablets) or the test…
- Trial name
- NCT04729998
- Testing
- Rivaroxaban film-coated tablet 20 mg, Xarelto® film-coated tablet 20 mg
- Where
- Russia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI)
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial…
- Conditions
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, AF - Atrial Fibrillation
- Trial name
- HERO-AF-AMI (NCT07583784)
- Testing
- DAT (DOAC+clopidogrel), DOAC monotherapy
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Chonnam National University Hospital
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
-Rivaroxaban is factor Xa inhibitor
- Trial name
- NCT03193502
- Testing
- rivaroxaban
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Deep Vein Thrombosis, Chronic Portal Vein Thrombosis
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the recurrence of thromboembolic event compared to an untreated group in patients with chronic portal vein thrombosis without high risk thrombophilia.
- Trial name
- RIPORT (NCT02555111)
- Testing
- Xarelto
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Blood Clot
A Prospective Pharmacodynamic Study of Rivaroxaban
The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of…
- Trial name
- NCT01743898
- Testing
- Rivaroxaban, no anticoagulation
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Atrial Fibrillation, Acute Coronary Syndrome
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT01812200
- Testing
- Dabigatran, Ticagrelor, ASA, Rivaroxaban, Ticagrelor, ASA, Phenprocoumon, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagulants (DOAC; apixaban…
- Trial name
- POCT-DOAC ext (NCT04679298)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Post Coronary Bypass Surgery Patients
Rivaroxaban Post Coronary Bypass Surgery
Post coronary bypass patients were randomized to receiving aspirin alone or aspirin and low dose rivaroxaban
- Trial name
- NCT06019741
- Testing
- Rivaroxaban and aspirin 80, Aspirin 80
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Shiraz University of Medical Sciences
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Rivaroxaban, Cancer-associated Thrombosis
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary…
- Conditions
- Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding
- Trial name
- NCT01989845
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Seoul National University Hospital
Venous Thrombosis, Neoplasms
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients.
- Conditions
- Venous Thrombosis, Neoplasms, Anticoagulants
- Trial name
- ONCO PE (NCT04724460)
- Testing
- Long DOAC, Short DOAC
- Where
- Japan
- Volunteers
- 179 people
- Sponsor
- Takeshi Morimoto
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Coagulation Disorder
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts: Part 1: Single dose of…
- Trial name
- NCT06372483
- Testing
- VMX-C001, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.